Blogs & Articles

Discover why LIMS, ELN, and MES fall short in managing complex scientific workflows—

Discover how Signals One and Signals Synergy from Revvity Signals unify data, enhance collaboration, and accelerate rare disease research through integrated digital solutions.

This article highlights how scientific data strategy is becoming a boardroom priority in Indian biopharma, driving compliance, faster approvals, and global competitiveness through digitized lab systems and robust data infrastructure.

​Move beyond cost savings to measure scientific ROI using modern digital transformation metrics like time-to-insight, reproducibility, collaboration, and scalability.

Explore how validation in the cloud can become your competitive advantage. Learn how to stay compliant without slowing down.

Discover how Revvity Signals can help build an ELN that scales with modern day research for a future-proof lab.

Why Data Integrity Matters in Indian Biopharma
India is one of the world's largest generic drug manufacturers, supplying a significant portion of global medicines. But with that scale comes scrutiny — particularly from regulators like the FDA, EMA, and MHRA.

Learn how interoperable scientific software solutions break down data silos, reduce errors, and accelerate R&D by connecting tools, workflows, and teams seamlessly.

Reimagining Clinical Development in the Age of AI

2025 was a year defined by momentum, across science, data, and the rapidly evolving ecosystems that enable modern R&D. Organizations around the world continued to push for greater connectivity, smarter workflows, and more unified scientific environments.